Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Peck

MOHS-Micrographic Surgery Richland, WA Medical Doctor

NPI 1457514689 CMS profile 247936

112 Columbia Point Dr Ste 105, Richland, WA 99352

Open in the dashboard

General payments

$9,298

636 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Peck of Richland, WA is reported in the CMS Open Payments database as having received $9,298 across 636 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,627 186
2024 General $1,992 144
2023 General $1,687 116
2022 General $1,024 61
2021 General $556 38
2020 General $517 32
2019 General $895 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Peck
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jeremy Peck were reported at $2,627. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jeremy Peck MOHS-Micrographic Surgery median Middle half National median
2019 $895 $316 $106–$785 $163
2020 $517 $162 $68–$412 $114
2021 $556 $243 $87–$654 $132
2022 $1,024 $300 $102–$887 $149
2023 $1,687 $364 $125–$1,010 $160
2024 $1,992 $445 $142–$1,108 $164
2025 $2,627 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,286 180 payments
  2. Janssen Biotech, Inc. $1,921 157 payments
  3. Lilly USA, LLC $862 44 payments
  4. UCB, Inc. $559 33 payments
  5. Sun Pharmaceutical Industries Inc. $482 20 payments
  6. Amgen Inc. $428 20 payments
  7. Genzyme Corporation $405 21 payments
  8. Novartis Pharmaceuticals Corporation $317 23 payments
  9. E.R. Squibb & Sons, L.L.C. $239 18 payments
  10. Organogenesis Inc. $216 20 payments
  11. Other $1,583 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,777 626 payments
  2. Education $521 10 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,789 148 payments
  2. SKYRIZI $1,054 88 payments
  3. TALTZ $794 41 payments
  4. RINVOQ $760 54 payments
  5. STELARA $490 33 payments
  6. Bimzelx $486 29 payments
  7. Otezla $400 18 payments
  8. SIMPONI ARIA $340 25 payments
  9. SIMPONI $340 25 payments
  10. DUPIXENT $336 17 payments
  11. Other $3,975 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,085

Median for Dermatology: 534

Drug cost

$725,171

Median for Dermatology: $67,151

Branded share of claims

10.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 13 $292,626
Dupixent Pen Dupilumab Brand 53 $229,469
Rinvoq Upadacitinib Brand 28 $177,083
Clobetasol Propionate Generic 228 $13,832
Triamcinolone Acetonide Generic 353 $3,271
Tacrolimus Generic 13 $2,283
Doxycycline Hyclate Generic 103 $2,263
Imiquimod Generic 66 $1,269
Tretinoin Generic 13 $948
Terbinafine Hcl Generic 21 $537

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$746,334

Of which drugs: $341,551

Medicare patients

1,476

Average age 76

Services billed

6,323

683 women, 793 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 46%
Diabetes 22%
Ischemic heart disease 19%
Chronic kidney disease 19%
Atrial fibrillation 17%
Cancer 15%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 45 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $450
$450 — —
SKYRIZI
  • AbbVie, Inc. $328
$328 13 —
RINVOQ
  • AbbVie, Inc. $218
$218 28 —
Bimzelx
  • UCB, Inc. $169
$169 — —
DUPIXENT
  • GENZYME CORPORATION $135
$135 53 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

636 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record